Tocilizumab in the treatment of adult rheumatoid arthritis

被引：14

作者：

Sanmarti, Raimon ^{[1
]}

Ruiz-Esquide, Virginia ^{[1
]}

Bastida, Carla ^{[2
]}

Soy, Dolor ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Rheumatol Serv, Arthritis Unit, Barcelona, Catalonia, Spain

[2] Hosp Clin Barcelona, Pharm Serv, Barcelona, Catalonia, Spain

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 06期

关键词：

biologic DMARDs; IL-6; receptor; rheumatoid arthritis; tocilizumab; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; ROUTINE CLINICAL-PRACTICE; PLACEBO-CONTROLLED TRIAL; BODY-MASS INDEX; DOUBLE-BLIND; IL-6; RECEPTOR; SUBCUTANEOUS TOCILIZUMAB;

D O I：

10.2217/imt-2017-0173

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rheumatoid arthritis (RA) is the most prevalent immune-mediated chronic rheumatic disease and is associated with joint destruction and disability. Therapeutic strategies, including biological disease-modifying antirheumatic drugs (bDMARDs) have improved the prognosis and quality of life of RA patients. Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA. Of particular interest is the demonstration of its effectiveness in monotherapy in comparison with other bDMARDs. Recent observational studies have shown good results for the safety profile of TCZ with no new alert signals.

引用

页码：447 / 464

页数：18

共 50 条

[41] Clinical safety of tocilizumab in rheumatoid arthritis
Bannwarth, Bernard
Richez, Christophe
[J]. EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 123 - 131
[42] Correction to: Tocilizumab: A Review in Rheumatoid Arthritis
Lesley J. Scott
[J]. Drugs, 2018, 78 (2) : 285 - 285
[43] Tocilizumab versus adalimumab for rheumatoid arthritis
Felson, David T.
[J]. LANCET, 2013, 382 (9890): : 394 - 395
[44] The role of tocilizumab in the management of rheumatoid arthritis
Ash, Zoe
Emery, Paul
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) : 1277 - 1289
[45] ADAM-10 AS A TOCILIZUMAB TREATMENT PREDICTIVE FACTOR IN RHEUMATOID ARTHRITIS
Isozaki, T.
Nishimi, S.
Nishimi, A.
Ishii, S.
Tokunaga, T.
Furuya, H.
Wakabayashi, K.
Kasama, T.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 222 - 223
[46] Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
Narvaez, Javier
Diaz-Torne, Cesar
Magallares, Berta
Victoria Hernandez, Maria
Reina, Delia
Corominas, Hector
Sanmart, Raimon
Rodriguez de la Serna, Arturo
Maria Llobet, Josep
Nolla, Joan M.
[J]. PLOS ONE, 2015, 10 (04):
[47] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
Diamantopoulos, Alex
Finckh, A.
Huizinga, T.
Sungher, D. K.
Sawyer, L.
Neto, D.
Dejonckheere, F.
[J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
[48] Successful Treatment with Tocilizumab in a Case of Intralymphatic Histiocytosis Associated with Rheumatoid Arthritis
Nakajima, Toshiki
Kawabata, Daisuke
Nakabo, Shuichiro
Miyagawa-Hayashino, Aya
Yukawa, Naoichiro
Yoshifuji, Hajime
Ohmura, Koichiro
Fujii, Takao
Mimori, Tsuneyo
[J]. INTERNAL MEDICINE, 2014, 53 (19) : 2255 - 2258
[49] CHANGES IN METABOLIC PROFILE DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
Tournadre, A.
Pereira, B.
Frayssac, T.
Tatar, Z.
Malochet-Guinamand, S.
Verny, M. -A.
Mathieu, S.
Couderc, M.
Dubost, J. J.
Soubrier, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 685 - 685
[50] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
Alex Diamantopoulos
A. Finckh
T. Huizinga
D. K. Sungher
L. Sawyer
D. Neto
F. Dejonckheere
[J]. PharmacoEconomics, 2014, 32 : 775 - 787

← 1 2 3 4 5 →